DaVita (NYSE:DVA) Price Target Cut to $140.00 by Analysts at Bank of America

DaVita (NYSE:DVA) had its price objective decreased by Bank of America from $145.00 to $140.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Bank of America currently has an underperform rating on the stock.

DVA has been the topic of several other research reports. Truist Financial set a $148.00 target price on DaVita in a research note on Friday, August 8th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, August 22nd. Finally, Barclays lowered their target price on DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, DaVita presently has a consensus rating of “Reduce” and an average target price of $158.00.

DaVita Trading Down 3.2%

NYSE DVA opened at $132.29 on Wednesday. The stock has a market cap of $9.46 billion, a P/E ratio of 13.01, a PEG ratio of 0.98 and a beta of 1.13. The company’s fifty day simple moving average is $138.83 and its 200-day simple moving average is $141.66. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. DaVita has a 52 week low of $126.07 and a 52 week high of $179.60.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts predict that DaVita will post 10.76 EPS for the current fiscal year.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider owned 26,038 shares of the company’s stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DVA. Ameriprise Financial Inc. lifted its stake in DaVita by 27.2% in the fourth quarter. Ameriprise Financial Inc. now owns 32,545 shares of the company’s stock valued at $4,867,000 after buying an additional 6,951 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in DaVita during the fourth quarter worth $322,000. Ethic Inc. increased its holdings in DaVita by 116.7% during the fourth quarter. Ethic Inc. now owns 4,345 shares of the company’s stock worth $650,000 after buying an additional 2,340 shares during the last quarter. Ensign Peak Advisors Inc increased its holdings in DaVita by 57.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 31,292 shares of the company’s stock worth $4,680,000 after buying an additional 11,395 shares during the last quarter. Finally, Lighthouse Investment Partners LLC bought a new position in DaVita during the fourth quarter worth $1,645,000. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.